MX-1
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
MX-1 |
Humane Brust Adenokarzinom Zell-Linie |
300296 |
cryovial |
375,00 |
MX-1 |
Humane Brust Adenokarzinom Zell-Linie |
330296 |
vital |
465,00 |
| Designation: | MX-1 |
| Depositor: | CLS |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 40 years of age |
| Gender: | female |
| Tissue: | Breast |
| Morphology: | epithelial |
| Celltype: | infiltrating duct carcinoma |
| Growth Properties: | monolayer |
| Description: | The MX-1 cell line has been established in vitro from the primary infiltrating duct carcinoma of a 40 year-old female; oestrogen receptors negative. |
| Culture Medium: | DMEM:Ham's F12 (1:1 mixture) supplemented with 2 mM L-glutamine and 5-10% fetal bovine serum. |
| Subculturing: | Remove medium, add fresh 0.025% trypsin/0.02% EDTA solution and incubate at 37°C until the cells detach. Add fresh medium, aspirate to disperse the cells and centrifuge at 800 rpm for 3 minutes. Add fresh medium to the pellet and dispense into new flasks. |
| Split Ratio: | A ratio of 1:2 or maximum 1:3 is recommended |
| Fluid Renewal: | every 2 to 3 days |
| Doubling Time: | 27 hours |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice |
References: Ovejera AA et al. Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci 8: 50-6, 1978. Houchens DP et al. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63: 473-6, 1979. Anderson WK. Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice. Cancer Res 42: 2168-70, 1982. Ceriani RL et al. Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components. Cancer Res 47: 532-40, 1987. Feichter G et al. Comparison of S-phase fractions measured by flow cytometry and autoradiography in human transplant tumors. Cytometry 9: 605-11, 1988. Ceriani RL et al. Experimental therapy of human breast tumors with 131I-labeld monoclonal antibodies prepared against the human milk fat globule. Cancer Res 48: 4664-72, 1988. Marxsen JH et al. Vascular endothelial growth factor gene expression in the human breast cancer cell line MX-1 is controlled by O2 availability in vitro and in vivo. Ann Anat 183: 243-9, 2001. Hilger I et al. Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice. Radiology 218: 570-5, 2001. Lerchen HG et al. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 44: 4186-95, 2001. Schmitt O et al. Preferential Topography of Proteins Regulating Vascularization and Apoptosis in a MX-1 Xenotransplant After Treatment With Hypoxia, Hyperthermia, Ifosfamide, and Irradiation. Am J Clin Oncol 24: 325-36, 2002. Mitsui S et al. Antitumor activity of polyoxomolybdate, [NH3Pri]6[Mo7O24].3H2O, against, human gastric cancer model. Biomed Pharmacother 60: 353-8, 2006. Yanagie H et al. Anticancer activity of polyoxomolybdate. Biomed Pharmacother 60: 349-52, 2006. | |
